K. Jochmans MD, PhD

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Summary

Venous thrombosis is a common complication in cancer patients and thromboembolism is the second most common cause of death. Several practice guidelines provide recommendations for the management of cancer-associated thrombosis. However, these guidelines do not sufficiently cover commonly encountered clinical challenges. With this expert panel, consisting of medical oncologists, haematologists, internists and thrombosis specialists, we aimed to develop a practical Belgian guidance for adequate prevention and treatment of cancer-associated thrombosis that covered several challenging situations encountered in daily clinic. This paper discusses the following topics: type and treatment duration of anticoagulant therapy, recurrent VTE despite anticoagulation, anticoagulation in case of renal impairment, liver disease and thrombocytopenia, the role of anti-Xa monitoring, central venous catheter-associated thrombosis, the position of direct oral anticoagulants and thromboprophylaxis, both in ambulatory and hospitalised patients. For an overview of the recommendations formulated by the expert panel, we refer to the key messages for clinical practice in this article.

(BELG J HEMATOL 2016;7(6):217–23)

PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation

A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation

P1.18 Monoclonal B-cell lymphocytosis with a lymphoma phenotype: characterization and prognosis of a patient cohort

A-108 Belgian multicenter study into von Willebrand Disease (B-Will Study): First results